Building Momentum in Precision Oncology Across Latin America
At the 1st Symposium on Genomics and Precision Oncology in Brazil (April 10–11), over 300 oncologists gathered to advance the future of cancer care and the Gene Solutions Brazil team was proud to contribute. A major standout was the insightful session on “Liquid Biopsy: Detection of ctDNA and Minimal Residual Disease (MRD)” led by […]
Elevating Multi-Cancer Early Detection Through Genomic Innovation
On 7 February 2026, the Gene Solutions Hong Kong team co-organized a public health talk in Hong Kong that brought together 40+ participants—including patients’ families and health‑conscious individuals—to address a growing concern: the city’s rising cancer burden. Cancer incidence continues to climb, yet many malignancies develop with non-specific symptoms that are easily mistaken for common […]
Gene Solutions & ATC introducing Oncology Portfolio in Türkiye at the 2nd International Hereditary Cancers Congress with Industry Symposium & Oral Presentation
At the 2nd International Hereditary Cancers Congress (IHCC) held in Antalya, Türkiye (February 5–8, 2026), Gene Solutions – co-hosted with its Türkiye’s distribution partner – ATC – organized a dedicated industry satellite symposium and delivered an oral presentation. The sessions explored how ctDNA, AI-powered multi-omics can advance outcomes across the cancer continuum, from early screening […]
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative method, combining tumor-informed and tumor-agnostic approach, addresses a critical gap in precision oncology: the challenge of obtaining high-quality tissue specimens in diverse clinical settings. Enhanced […]
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together leading experts to discuss how Next-Generation Sequencing (NGS), machine learning, and advanced molecular diagnostics are reshaping prenatal care in India and beyond. 🔬 A New Era: AI + […]
World Cancer Day 2026 – 1,000 MCED Tests for Early Detection by Gene Solutions Malaysia
Early detection saves lives—but access must reach everyone. In conjunction with World Cancer Day 2026, Gene Solutions Malaysia and the National Cancer Society Malaysia (NCSM) officially signed a Memorandum of Understanding (MOU), marking the soft launch of the Early4Life Campaign. This partnership represents a shared commitment to expanding cancer awareness and improving access to early […]
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
IRVINE, Calif. — January 21, 2026 — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring. […]
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA Assays for Recurrence Detection in Early-Stage Non-Small Cell Lung Cancer.” This first-of-its-kind study delivers a direct, real-world comparison of two ctDNA-based minimal residual disease (MRD) […]
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but also a commitment to solving real clinical problems across the cancer care continuum. EARLY DETECTION — WHEN ONE BLOOD SAMPLE NEEDS TO CAPTURE MORE […]
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping oncology – from early detection to MRD-guided treatment decisions and clinical utility standards. Chaired by Prof. Herbert Ho Fung Loong (The Chinese University of Hong […]